Clinical evaluation of palliative therapy for unresectable primary liver cancer
- 15 July 1986
- Vol. 58 (2) , 329-331
- https://doi.org/10.1002/1097-0142(19860715)58:2<329::aid-cncr2820580220>3.0.co;2-d
Abstract
Ninety-nine patients with unresectable primary liver cancer were treated with ligation of the hepatic artery (LHA), intra-arterial infusion chemotherapy (IAIC) or transcatheter arterial embolization (TAE) between 1960 and 1983. A statistical study was made of therapeutic effects and prognosis. The results are as follows: (1) The mean survival time of 14 patients treated with LHA was about 5 months. (2) The survival time of the LHA + IAIC with mitomycin C group was not prolonged as compared with that of the LHA group, but LHA + IAIC with Adriamycin (doxorubicin) group showed a significant prolongation of survival time over the LHA group. (3) In the LHA + IAIC with Adriamycin group, the mean survival time was 12.8 months and the 1-year survival rate was 37.5%. (4) Factors including age, presence of liver cirrhosis, number of involved segments, and degree of anaplasia graded on Edmondson's criteria did not influence survival time. Cancer 58:329–331, 1986.This publication has 6 references indexed in Scilit:
- Further experience in treating patients with hepatocellular carcinoma in UgandaCancer, 1980
- Primary liver cancers in JapanCancer, 1980
- THERAPY FOR HEPATOCELLULAR CANCER WITH INTRA-HEPATIC ARTERIAL ADRIAMYCIN AND 5-FLUOROURACIL COMBINED WITH WHOLE-LIVER IRRADIATION - NORTHERN CALIFORNIA ONCOLOGY GROUP-STUDY1979
- Hepatic artery ligation and adriamycin infusion chemotherapy for hepatomaCancer, 1978
- ADRIAMYCIN THERAPY IN AMERICAN PATIENTS WITH HEPATOCELLULAR CARCINOMA1977
- Treatment of hepatocellular carcinoma with adriamycin.Preliminary communicationCancer, 1975